AI Article Synopsis

  • G-protein-coupled receptors (GPCRs), especially the β2-adrenergic receptor (β2AR), are vital for drug targeting in treating pulmonary diseases.
  • Our study used coarse-grained molecular dynamics simulations to analyze how salmeterol and salbutamol interact with membranes and the β2AR, revealing that drug molecules often use the receptor surface for better membrane permeability.
  • Findings indicate that enhancing drug interactions with GPCR surfaces could improve therapeutic effectiveness, presenting new avenues for drug development.

Article Abstract

G-protein-coupled receptors (GPCRs) play a crucial role in modulating physiological responses and serve as the main drug target. Specifically, salmeterol and salbutamol, which are used for the treatment of pulmonary diseases, exert their effects by activating the GPCR β2-adrenergic receptor (β2AR). In our study, we employed coarse-grained molecular dynamics simulations with the Martini 3 force field to investigate the dynamics of drug molecules in membranes in the presence and absence of β2AR. Our simulations reveal that, in more than 50% of the flip-flop events, the drug molecules use the β2AR surface to permeate the membrane. The pathway along the GPCR surface is significantly more energetically favorable for the drug molecules, which was revealed by umbrella sampling simulations along spontaneous flip-flop pathways. Furthermore, we assessed the behavior of drugs with intracellular targets, such as kinase inhibitors, whose therapeutic efficacy could benefit from this observation. In summary, our results show that β2AR surface interactions can significantly enhance the membrane permeation of drugs, emphasizing their potential for consideration in future drug development strategies.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jpclett.4c02875DOI Listing

Publication Analysis

Top Keywords

drug molecules
16
membrane permeation
8
β2ar surface
8
drug
6
g-protein-coupled receptor
4
surface
4
receptor surface
4
surface creates
4
creates favorable
4
favorable pathway
4

Similar Publications

Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease, and podocyte injury is one of the major contributors to DKD. As a crucial transcriptional factor that regulates cellular response to oxidative stress, nuclear factor erythroid 2-related factor 2 (Nrf2) is an attractive therapeutic target for DKD. In this study, we evaluated the therapeutic potential of DDO-1039, a novel small-molecule Nrf2 activator developed with protein-protein interaction strategy, on podocyte injury in DKD.

View Article and Find Full Text PDF

Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant primary brain tumors in young adults. This condition imposes a substantial burden on patients and their caregivers, marked by neurocognitive deficits and high mortality rates due to tumor progression, coupled with significant morbidity from current treatment modalities. Although surgery, radiation therapy, and chemotherapy improve survival, these treatments can adversely affect cognitive function, quality of life, finances, employment status, and overall independence.

View Article and Find Full Text PDF

Targeting Remyelination in Spinal Cord Injury: Insights and Emerging Therapeutic Strategies.

CNS Neurosci Ther

December 2024

Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang, China.

Introduction: Spinal cord injury (SCI) is a severe neurological disease characterized by significant motor, sensory, and autonomic dysfunctions. SCI is a major global disability cause, often resulting in long-term neurological impairments due to the impeded regeneration and remyelination of axons. A SCI interferes with communication between the brain and the spinal cord networks that control neurological functions.

View Article and Find Full Text PDF

Advances in biomarkers for immunotherapy in small-cell lung cancer.

Front Immunol

December 2024

Medical Oncology Translational Research Lab, Jilin Cancer Hospital, Changchun, China.

Small-cell lung cancer (SCLC) is a refractory cancer with rapid growth and high aggressiveness. Extensive-stage SCLC is initially sensitive to chemotherapy; however, drug resistance and recurrence occur rapidly, resulting in a poor survival outcome due to lack of subsequently efficient therapy. The emergence of immune checkpoint inhibitors (ICIs) generated a new landscape of SCLC treatment and significantly prolonged the survival of patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!